创新药异动丨荣昌生物核心产品泰它西普获欧盟孤儿药认证、5年专利补偿

每日经济新闻
25 Jun

荣昌生物近期公告称,其核心产品泰它西普获得国家知识产权局授予的专利权期限补偿,补偿天数为1827天,使得该药的专利权期满终止日从2027年6月15日延长到2032年6月15日。专利保护期延长至2032年,可为公司核心产品提供额外5年的市场保护,将显著提升公司药品在中国市场的独占销售窗口期,有利于中长期业绩增长,提升核心竞争力。此外,泰它西普6月也获得欧盟委员会(EC)授予的孤儿药资格认定(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10